Therapy Pipeline uniQure is advancing a gene therapy pipeline with AMT-130 for Huntington's disease and AMT-260 for refractory epilepsy, indicating ongoing product development with potential partnering or collaboration opportunities around CNS genetic disorders.

Regulatory Progress Regulatory submissions and potential accelerated-approval pathways for AMT-130 are in focus, suggesting sales opportunities connected to regulatory milestones, payer discussions, and early access programs in the US and UK.

Financial Flexibility Strengthened balance sheet with a large follow-on funding extending cash runway into 2030, enabling longer-term collaboration discussions, co-development deals, and readiness for commercialization investments.

Strategic Partnerships Platform approach and partnered therapies imply existing or potential collaboration models with pharma companies seeking gene therapy capabilities, enabling BD opportunities in licensing, manufacturing support, or joint ventures.

Clinical Milestones Upcoming data readouts and topline results, including four-year AMT-130 data and early signals from AMT-260, present near-term selling moments for partnerships, advisory roles, and accelerated access conversations with stakeholders.